Silence Therapeutics to Participate in Fireside Chat at the Chardan Virtual Genetic Medicines Conference
Silence Therapeutics (AIM: SLN, Nasdaq: SLN) will participate in a fireside chat during the Chardan Virtual Genetic Medicines Conference on October 5 at 8:30 a.m. EDT. The event highlights the company's innovative siRNA therapeutics aimed at addressing diseases with significant unmet medical needs. A live webcast will be available on their website, and an archived replay will follow. Silence's ongoing projects include SLN360 for cardiovascular risk and SLN124 for iron-loading anemia.
- None.
- None.
Silence Therapeutics to Participate in Fireside Chat at the Chardan Virtual Genetic Medicines Conference
28 September 2021
LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will participate in a fireside chat at the Chardan Virtual Genetic Medicines Conference on Tuesday, October 5th at 8:30 a.m. EDT / 1:30 p.m. BST.
A live webcast of the fireside chat can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available on the Company’s website following the conference.
Enquiries:
| Silence Therapeutics plc Gem Hopkins, Head of IR and Corporate Communications ir@silence-therapeutics.com | Tel: +1 (646) 637-3208 |
| Investec Bank plc (Nominated Adviser and Broker) Daniel Adams/Gary Clarence | Tel: +44 (0) 20 7597 5970 |
| European PR Consilium Strategic Communications Mary-Jane Elliott/ Angela Gray / Chris Welsh silencetherapeutics@consilium-comms.com | Tel: +44 (0) 20 3709 5700 |
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron-loading anemia conditions. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.
FAQ
When will Silence Therapeutics participate in the Chardan Virtual Genetic Medicines Conference?
How can I access the Silence Therapeutics fireside chat?
What are the key products of Silence Therapeutics?
What is the focus of Silence Therapeutics' research?
What platforms does Silence Therapeutics use for drug development?
